Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis (original) (raw)

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

The New England journal of medicine, 2014

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients

2013

The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study

Simone Baldovino

Oncotarget

View PDFchevron_right

Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain Ancaassociated Vasculitis Remissions Results of a Prospective Randomizedcontrolled Phase 3 Trial

Catherine Henney

2017

View PDFchevron_right

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

Ulrich Specks, Cees Kallenberg

New England Journal of Medicine, 2010

View PDFchevron_right

Induction treatment of ANCA-associated vasculitis with a single dose of rituximab

Alan Salama

Rheumatology, 2014

View PDFchevron_right

Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly

Roberta Fenoglio

Kidney and Blood Pressure Research, 2020

View PDFchevron_right

Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort

pascale chasseur

Acta Clinica Belgica, 2019

View PDFchevron_right

Is Rituximab Superior to Cyclophosphamide for ANCA-Associated Vasculitis for Induction of Remission, and with a Better Safety Profile?

Luis Adolfo Gomez Espinoza

Current Rheumatology Reports, 2010

View PDFchevron_right

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis

Shahd Hafiz

Case Reports in Rheumatology, 2016

View PDFchevron_right

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis; Case Report

Shahd Hafiz

View PDFchevron_right

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives

Luca Quartuccio

Journal of Clinical Medicine

View PDFchevron_right

Low-dose rituximab as induction therapy for ANCA-associated vasculitis

Yoshioki Yamasaki

Clinical Rheumatology, 2019

View PDFchevron_right

#4183 a Phenotypic Driven Rituximab Maintenance Approach is Effective and Safe in Patients with Anca Associated Vasculitis

Alice Guerini

Nephrology Dialysis Transplantation

View PDFchevron_right

Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial

Lucio Manenti

PloS one, 2017

View PDFchevron_right

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Study

ARIEL SALINAS

Arthritis & Rheumatology

View PDFchevron_right

Treatment of ANCA-Associated Vasculitis in Adults

Aurore Fifi-Mah

Updates in the Diagnosis and Treatment of Vasculitis, 2013

View PDFchevron_right

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

Frédérique Bocquentin

Rheumatology, 2020

View PDFchevron_right

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis

Alan Salama

Arthritis & Rheumatism, 2009

View PDFchevron_right

Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis

Bruno Legallicier

JAMA Network Open

View PDFchevron_right

Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement

Ulrich Specks, Cees Kallenberg

Journal of the American Society of Nephrology : JASN, 2014

View PDFchevron_right

[The role of rituximab in the treatment of ANCA-associated systemic vasculitis]

Pierre-yves Martin

Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

View PDFchevron_right

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Pierre Charles MEBE

Annals of Internal Medicine, 2020

View PDFchevron_right

Maintenance with Rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis

Vessel Plus

Vessel Plus, 2020

View PDFchevron_right

Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis

Isabelle Guichard

Rheumatology, 2021

View PDFchevron_right

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

Dominique MERRIEN

The New England journal of medicine, 2008

View PDFchevron_right

Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment

Yannick Pouliot

Arthritis research & therapy, 2015

View PDFchevron_right

Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis

Elisa Menegatti

American Journal of Nephrology, 2011

View PDFchevron_right

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis

S. Laurino

Arthritis & Rheumatism, 2012

View PDFchevron_right

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis (original) (raw)

Related papers